PMID- 27568115
OWN - NLM
STAT- MEDLINE
DCOM- 20171024
LR  - 20220331
IS  - 1876-7591 (Electronic)
IS  - 1876-7591 (Linking)
VI  - 9
IP  - 11
DP  - 2016 Nov
TI  - Prognostic Value of Late Gadolinium Enhancement CMR in Systemic Amyloidosis.
PG  - 1267-1277
LID - S1936-878X(16)30465-X [pii]
LID - 10.1016/j.jcmg.2016.01.036 [doi]
AB  - OBJECTIVES: The aim of this study was to access the prognostic implication of 
      late gadolinium enhancement (LGE) in patients with systemic amyloidosis 
      undergoing cardiac magnetic resonance (CMR). BACKGROUND: Cardiac amyloidosis 
      confers significantly worse prognosis in patients with systemic amyloidosis. CMR 
      imaging has emerged as an attractive noninvasive modality to diagnose cardiac 
      involvement in patients with systemic amyloidosis. We performed a systemic review 
      and meta-analysis to evaluate the prognostic role of LGE-CMR imaging in patients 
      with systemic amyloidosis. METHODS: Electronic databases MEDLINE, PubMed, Embase, 
      and Cochrane were systematically searched to identify studies evaluating the 
      association between LGE-CMR and prognosis in systemic amyloidosis with cardiac 
      involvement. The present study was designed to systematically review and assess 
      the association between LGE and the primary endpoint of all-cause mortality. A 
      random effects model was used to calculate a pooled odds ratio using 
      inverse-variance weighting. RESULTS: Data were included from 7 studies with a 
      total of 425 patients and a mean follow-up of 25 months. Patients had a weighted 
      average age of 64 years and left ventricular ejection fraction of 59.2%; 67% were 
      male. Endomyocardial biopsy was positive for amyloidosis in 20%, whereas LGE was 
      present in 73% of patients. LGE-positive patients had increased overall mortality 
      compared with those without LGE (pooled odds ratio: 4.96; 95% confidence interval 
      [CI]: 1.90 to 12.93; p = 0.001). For the LGE group, the pooled death rate was 
      0.07 (95% CI: 0.03 to 0.19) events per year and for the LGE+ group, the rate was 
      0.25 (95% CI: 0.16 to 0.39 per year; p = 0.001). The proportion of patients with 
      cardiac biopsy within each study ranged from 3% to 68%, and the relationship 
      between LGE status and death did not vary according to cardiac biopsy proportion 
      across studies. CONCLUSIONS: LGE on CMR in patients with systemic amyloidosis 
      with known or suspected cardiac amyloidosis is associated with increased risk of 
      all-cause mortality.
CI  - Copyright (c) 2016 American College of Cardiology Foundation. Published by Elsevier 
      Inc. All rights reserved.
FAU - Raina, Sameer
AU  - Raina S
AD  - Department of Cardiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas. Electronic address: sameer.raina@hsc.wvu.edu.
FAU - Lensing, Shelly Y
AU  - Lensing SY
AD  - Department of Biostatistics, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
FAU - Nairooz, Ramez S
AU  - Nairooz RS
AD  - Department of Cardiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
FAU - Pothineni, Naga Venkata K
AU  - Pothineni NV
AD  - Department of Cardiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
FAU - Hakeem, Abdul
AU  - Hakeem A
AD  - Department of Cardiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas; Central Arkansas VA Health System, Little Rock, Arkansas.
FAU - Bhatti, Sabha
AU  - Bhatti S
AD  - Department of Cardiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
FAU - Pandey, Tarun
AU  - Pandey T
AD  - Department of Radiology, University of Arkansas for Medical Sciences, Little 
      Rock, Arkansas.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160824
PL  - United States
TA  - JACC Cardiovasc Imaging
JT  - JACC. Cardiovascular imaging
JID - 101467978
RN  - 0 (Contrast Media)
RN  - AU0V1LM3JT (Gadolinium)
SB  - IM
CIN - JACC Cardiovasc Imaging. 2016 Nov;9(11):1278-1279. PMID: 27568113
MH  - Amyloidosis/*diagnostic imaging/mortality/therapy
MH  - Biopsy
MH  - Cardiomyopathies/*diagnostic imaging/mortality/therapy
MH  - Chi-Square Distribution
MH  - Contrast Media/*administration & dosage
MH  - Female
MH  - Gadolinium/*administration & dosage
MH  - Humans
MH  - *Magnetic Resonance Imaging
MH  - Male
MH  - Middle Aged
MH  - Myocardium/pathology
MH  - Odds Ratio
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Risk Factors
MH  - Time Factors
OTO - NOTNLM
OT  - cardiac MRI
OT  - cardiac amyloidosis
OT  - late gadolinium enhancement
EDAT- 2016/08/29 06:00
MHDA- 2017/10/25 06:00
CRDT- 2016/08/29 06:00
PHST- 2015/11/30 00:00 [received]
PHST- 2016/01/11 00:00 [revised]
PHST- 2016/01/14 00:00 [accepted]
PHST- 2016/08/29 06:00 [pubmed]
PHST- 2017/10/25 06:00 [medline]
PHST- 2016/08/29 06:00 [entrez]
AID - S1936-878X(16)30465-X [pii]
AID - 10.1016/j.jcmg.2016.01.036 [doi]
PST - ppublish
SO  - JACC Cardiovasc Imaging. 2016 Nov;9(11):1267-1277. doi: 
      10.1016/j.jcmg.2016.01.036. Epub 2016 Aug 24.